Aera Therapeutics is focused on advancing genetic medicines, which have the potential to revolutionize the treatment of various human diseases. The company aims to overcome the limitations of existing delivery technologies that hinder the broad application of these therapies. Central to Aera's approach is their proprietary protein nanoparticle (PNP) delivery platform, which utilizes endogenous human proteins that can self-assemble into capsid-like structures. This innovative platform is designed to package and transfer nucleic acid cargo, addressing many of the challenges associated with current delivery methods, such as safety, immunogenicity, and payload constraints.

In addition to the PNP platform, Aera has developed a proprietary therapeutic enzyme platform that features novel, compact, and programmable gene editing enzymes. These enzymes are engineered to be smaller in size, which may help mitigate the packaging and delivery challenges faced by traditional gene editing systems. Together, these technologies position Aera Therapeutics to unlock the full potential of genetic medicines across a wide range of therapeutic applications, ultimately aiming to provide more effective and targeted treatments for various diseases.

United States

Aera was founded with a vision to unlock the potential of genetic medicines across a broad range of modalities and therapeutic areas. Our protein nanoparticle (PNP) delivery platform leverages the discovery of endogenous, human proteins that can self-assemble to form capsid-like structures and that can package and transfer nucleic acid cargo. This platform has the potential to address many of the limitations of today’s delivery technologies and to enable various genetic medicine modalities.

Aera Therapeutics

Company Details